Archive for September, 2009

Recent Rosacea Blog Posts

Oracea worth $104m a year, good news for Sansrosa

According to a press release via Reuters, sales of Oracea were approximately $104 million for the twelve-month period ending July 2009. This figure is up almost 200% from the previously reported sales of $52.5 million in 2007. As you can see Oracea is a great source of revenue for Galderma. I believe that rosacea sufferers […]

Continue Reading

In a further confirmation that the low dose doxycycline market is a becoming a fighting ground, a recent press release states that Impax Laboratories has filed “Abbreviated New Drug Application ("ANDA") containing a paragraph IV certification for a generic version of ORACEA with the U.S. Food & Drug Administration ("FDA").” This is a challenge to […]

Continue Reading

This just published abstract from Lasers in Medical Science, shows that the extreme pain associated with pulsed dye laser, when used to treat port wine stains, can be relieved by using Pneumatic Skin Flattening (PSF). Pneumatic Skin Flattening uses a vacuum to compress the skin underneath the area being treated. Blood is eliminated from the […]

Continue Reading

FDA gets tough with Allergan over Aczone

The FDA has issued a warning letter to Allergan, the makers of Aczone for overstating the efficacy of Aczone and also for understating the possible side effects. In a sign that the FDA is watching carefully the claims that vendors use when advertising their products, the warning letter calls out a journal advertisement for Aczone […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.